DP
RCUS icon

Diadema Partners’s Arcus Biosciences RCUS Stock Holding History

Diadema Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.9M Sell
223,810
-14,332
-6% -$354K 0.87% 35
2026
Q1 		$5.14M Buy
+238,142
New +$5.14M 0.88% 38
2025
Q1 		– Sell
-165,965
Closed -$2.47M – 145
2024
Q4 		$2.47M Buy
+165,965
New +$2.71M 1.06% 30

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Diadema Partners's RCUS Position: Q2 2026 in Review

Diadema Partners reduced its Arcus Biosciences (RCUS) stake by 6% in Q2 2026, selling an estimated $354K and leaving 223,810 shares worth $6.9M. The position accounts for 0.87% of the portfolio, ranked #35.

Diadema Partners first reported a position in RCUS in Q4 2024 and has held it in 3 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Diadema Partners held 223,810 shares of Arcus Biosciences worth $6.9M as of Q2 2026.
  • Diadema Partners sold 14,332 Arcus Biosciences shares in Q2 2026, an estimated $354K.
  • Arcus Biosciences made up 0.87% of Diadema Partners's portfolio in Q2 2026, its #35 holding.
  • Diadema Partners first reported a position in Arcus Biosciences in Q4 2024 and has held it in 3 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.